

PTO/SB/08a (08-03)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3**Complete if Known**

Application Number	10/634,162
Filing Date	August 5, 2003
First Named Inventor	Michael William Willson
Art Unit	1625
Examiner Name	Evelyn Mei Huang
Attorney Docket Number	PC 25239A

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
<i>SH</i>		WO 01/12611 A1	02/22/2001	Blagg		
		WO 01/63244 A1	08/30/2001	Chen, et al.		
		WO 02/34726 A2/A3	05/02/2002	Noe, et al.		
<i>SH</i>		WO 02/34753 A2/A3	05/02/2002	Bronk, et al.		

Examiner Signature	<i>E. Huang</i>	Date Considered	<i>7/2/04</i>
--------------------	-----------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/634,162	
			Filing Date	August 5, 2003	
			First Named Inventor	Michael William Wilson	
			Art Unit	1625	
			Examiner Name	Evelyn Mei Huang	
Sheet	3	of	4	Attorney Docket Number	PC 25239A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
<i>SW</i>		BILLINGHURST, et al., Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase, Arthritis & Rheumatism, 2000; 43(3): 664-672		
		BILLINGHURST, et al., Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage, J. Clin Invest., 1997; 99(7): 1534-1545		
		CHEN, et al., Structure-Based Design of a Novel, Potent, and selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design, J. Am. Chem. Soc., 2000; 122: 9648-9654		
		DAHLBERG, et al., Selective Enhancement of Collagenase-mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase 1 (Matrix Metalloproteinase2), Arthritis & Rheumatism, 2000; 43(3): 673-682		
		GILIS, et al., 1H-tetrazol-5-yl derivatives of chemotherapeutic agents of the nalidizic acid type, Eur. J. Med. Chem., 1980;15(6):499-502		
		HARRIS, The Oxidation of N-(2-Pyridyl) Thioureas. The Synthesis of [1.2.4] Thiazadiazolo [2,3-a] Pyridinium Salts, Aust. J. Chem., 1972;25(5): 993-1001		
		HIROTA, et al., Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]pyrimidines, and Quinazolines via Palladium-catalyzed Oxidative Coupling, Heterocycles, 1994; 37(1): 563-570		
		LEE, et al., Reactions of 3-Methylamino-5phenylthiophene with a,B-Unsaturated Esters and a, B-Unsaturated Nitriles, Journal of Heterocyclic Chemistry, 2000; 37: 363-372		
		LOVEJOY, et al., Crystal structures of MMP-1 AND -13 reveal the structural basis for selectivity of collagenase inhibitors, Nature Structural Biology, 1999; 6(3): 217-221		
<i>SW</i>		MITCHELL, et al., Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic, Cartilage, J. Clin. Invest., 1996; 97: 761-768		

Examiner Signature	<i>E. Huang</i>	Date Considered	7/2/04
-----------------------	-----------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/634,162		
		Filing Date	August 5, 2003		
		First Named Inventor	Michael William Wilson		
		Art Unit	1625		
		Examiner Name	Evelyn Mei Huang		
Sheet	4	of	4	Attorney Docket Number	PC 25239A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EM		MOY, et al., High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-3) Complexed with a Hydroxamic Acid Inhibitor, J. Mol. Biol., 2000; 302: 671-689	
EM		NEUHOLD, et al., Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice, J. Clin. Invest., 2001; 107(1): 35-44	
		CrossFire Accession no. ("AN") BRN 5584935 (XP002260703) - Commulative - no copy	
		CrossFire AN-BRN 8553626 (XP002260704) - Commulative - no copy	
		Embase Online ! AN EMB-1981068145 (XP002260702) - Commulative - no copy	
EM		Office Action mailed June 16, 2003 in U.S.S.N. 10/264,764	
EM		Search Report from PCT/IB03/03523	

Examiner Signature	<i>E. Huang</i>	Date Considered	7/2/04
--------------------	-----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.